A Phase 3 interventional study of Cardiovascular Polypill and Treatment Prevention for Secondary CV in Myocardial Infarction and Cardiovascular Disease, sponsored by Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III. Completed at 113 sites in 7 countries. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2025-05-23.
Sponsored by Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 131 studies in Myocardial Infarction with a site in Spain — 19 open to participants now, 27 under way, 7 of them phase 3. Myocardial Infarction · Spain.
Among the 131 studies in Myocardial Infarction with a site in Spain, this one is the 26th largest by enrollment of the 98 interventional ones that give a count, is one of 8 that started in 2016, is one of 33 in phase 3, and was the 68th registered.
2,273 studies on the registry are indexed under Myocardial Infarction; 373 are open to participants now.
Browse Myocardial Infarction studies →19 of the 131 studies in Myocardial Infarction with a site in Spain are open now. Recruiting first, the newest first:
Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz · Sites in Spain, Ireland, Latvia and 2 more countries
Ages 18+
Fundación para la Investigación del Hospital Clínico de Valencia · Sites in Spain
Ages 65+
Sergio Mies Padilla · Sites in Spain
Ages 18+
Novo Nordisk A/S · Sites in Spain, Austria, Denmark and 3 more countries
Ages 18+
Instituto de Investigación Biomédica de Salamanca · Sites in Spain
Ages 18+
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 256 Myocardial Infarction studies recruiting now, 173 (68%) set no upper age limit and 25 (10%) stop at 75 or younger; 17 take children under 18; 27 take healthy volunteers.
This study: 65 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
131 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 18 · Phase 3 35 · Phase 4 16
First in 2002; this study’s year is marked. 8 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 2,499 is above the median of 150 across 1,317 interventional studies indexed under Myocardial Infarction.
Median enrollment 445 across the 98 interventional studies, 1,498 across the 33 observational. Of the 91 that completed or were terminated, 29 (32%) have results posted.
This tab as a report to print or save as PDF → With an account.
51 of 131 have an industry lead sponsor. The 10 most frequent:
Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III is the lead sponsor of 11 studies on the registry; 3 are open to participants now.
Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III has 5 studies filed under Myocardial Infarction — fewer than ten, so there is no comparison to draw.
8 of the studies in Myocardial Infarction with a site in Spain that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06118281Phase 3Novo Nordisk A/SARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack | 2027-01-29 |
| NCT04957719Phase 3Viatris Innovation GmbHSelatogrel Outcome Study in Suspected Acute Myocardial Infarction | 2027-07 |
| NCT06799780IRCCS Azienda Ospedaliero-Universitaria di BolognaStudy on Post-acute Myocardial Infarction Ventricular Defect: Outcome Evalutation in Relation to Surgical Timing | 2026-11-30 |
| NCT04973397Centre hospitalier de l'Université de Montréal (CHUM)Vascular Events In Patients Undergoing Same-day Noncardiac Surgery (VALIANCE) Study | 2026-12 |
| NCT07268391Instituto de Investigación Biomédica de SalamancaUsing Advanced CT Scans and Blood Markers to Better Understand Heart Damage and Recovery After a Heart Attack | 2027-01 |
Add all 8 to your calendar (.ics) → With an account.
Among the 131 studies in Myocardial Infarction with a site in Spain, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy of a polypill strategy containing aspirin (100 mg), ramipril (2.5, 5 or 10 mgs), and atorvastatin (40 mgs) compared with the standard of care (usual care according to the local clinical practices at each participating country) in secondary prevention of major cardiovascular events (cardiovascular death, nonfatal myocardial infarction, nonfatal ischemic stroke, and urgent revascularization) in elderly patients with a recent myocardial infarction.
A total number of 2499 patients have been randomized (1:1) to treatment arms. Patients will be recruited across seven countries in Europe (Spain, Italy, Germany, France, Hungary, Poland, and Czech Republic).
Patients will be ≥65 years old and diagnosed with a type 1 myocardial infarction within 6 months prior to study enrolment.
Once the inclusion and exclusion criteria are confirmed, patients will be included in the study after signing informed consent.
Randomization will take place within 6 months of the index event (AMI type I) in a 1:1 ratio to one of the two arms:
Patients will be followed up for a minimum of 2 years and a maximum of 5 years.
There will be 3 follow up visits at month 6, 12 and 24 and telephone follow up calls at month 18, 36, 48 and 60
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subjects must be ≥65 years old, presenting with at least one of the following additional conditions:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients allocated to the usual care arm will receive standard of care therapies for secondary prevention according to the ESC guidelines. Drugs and doses will be left at the discretion of the treating physicians..
Drug: Treatment Prevention for Secondary CV
Patients allocated to the experimental arm will receive a cardiovascular polypill containing aspirin 100 mg, atorvastatin (40 or 20 mg) and ramipril (2.5, 5 or 10 mg) taken orally once a day.
Drug: Cardiovascular Polypill
Cardiovascular Polypill contains Aspirin, Atorvastatin and Ramipril. Participants will receive one of the following cardiovascular polypill: (A) Aspirin 100 mg, Atorvastatin 40mg, and Ramipril (2.5 mg, or 5 mg, or 10mg). or (B) Aspirin 100 mg, Atorvastatin 20mg, and Ramipril (2.5 mg, or 5 mg, or 10mg).
Also known as: Polypill
ESC Guideline (2013 guideline on management of stable coronary disease) recommended pharmacological treatment for event prevention.
Also known as: Antiplatelet agents, Lipid Lowering Agents, Renin-angiotensin-aldosterone system blockers
Major Cardiovascular Adverse Events (MACE)
The incidence of the first occurrence of any component of the following composite endpoint, as adjudicated by the Clinical Events Committee: * Cardiovascular death. * Any nonfatal type 1 myocardial infarction. * Any nonfatal ischemic stroke. * Any urgent coronary revascularization not resulting in death.
Time frame: Up to 5 years
Efficacy Endpoints
Treatment adherence at 6 months measured using the Morisky-Medication Adherence Scale (8 item) Questionnaire (MMAS-8). Results: Low adherence (0-5); Medium adherence (6-7) and High adherence (8). The number and percentage of patients with low (0-5), medium (6-7) and high (8) adherence will be reported by treatment group.
Time frame: 6 months
Safety Endpoints
All-cause mortality.
Time frame: Up to 5 Years
Efficacy Endpoints
Treatment adherence at 24 months measured using the Morisky-Medication Adherence Scale (8 item) Questionnaire (MMAS-8). Results: Low adherence (0-5); Medium adherence (6-7) and High adherence (8). The number and percentage of patients with low (0-5), medium (6-7) and high (8) adherence will be reported by treatment group.
Time frame: 2 years
Efficacy Endpoints
The systolic Blood Pressure measured in millimeters of mercury (mmHg) at visit 1 (6 months). Mean and standard deviation will be reported by treatment group.
Time frame: 6 months
Efficacy Endpoints
The systolic Blood Pressure measured in millimeters of mercury (mmHg) at visit 2 (12 months). Mean and standard deviation will be reported by treatment group.
Time frame: 12 months
Efficacy Endpoints
The systolic Blood Pressure measured in millimeters of mercury (mmHg) at visit 3 (24 months). Mean and standard deviation will be reported by treatment group.
Time frame: 2 years
Efficacy Endpoints
The Diastolic Blood Pressure measured in millimeters of mercury (mmHg) at visit 1 (6 months). Mean and standard deviation will be reported by treatment group. The frequency, mean and standard deviation at each visit will be reported by treatment group.
Time frame: 6 months
Efficacy Endpoints
The Diastolic Blood Pressure measured in millimeters of mercury (mmHg) at visit 2 (12 months). Mean and standard deviation will be reported by treatment group. The frequency, mean and standard deviation at each visit will be reported by treatment group.
Time frame: 12 months
Efficacy Endpoints
The Diastolic Blood Pressure measured in millimeters of mercury (mmHg) at visit 3 (24 months). Mean and standard deviation will be reported by treatment group. The frequency, mean and standard deviation at each visit will be reported by treatment group.
Time frame: 2 years
Efficacy Endpoints
Low-density lipoprotein (LDL) cholesterol levels measured in mg/dL at visit 2 (12 months). Mean and standard deviation will be reported by treatment group. The frequency, mean and standard deviation at each visit will be reported by treatment group.
Time frame: 12 months
Efficacy Endpoints
Low-density lipoprotein (LDL) cholesterol levels measured in mg/dL at visit 3 (24 months). Mean and standard deviation will be reported by treatment group. The frequency, mean and standard deviation at each visit will be reported by treatment group.
Time frame: 2 years
Efficacy Endpoints
The incidence of the first occurrence of any component of the following composite endpoint, as adjudicated by the Clinical Events Committee: Cardiovascular death (CV death); Acute Myocardial Infarction (MI) type 1; stroke. Measured in number of cases.
Time frame: Up to 5 years
Efficacy Endpoints
The incidence of the first occurrence of the Cardiovascular (CV) death. Measured in number of cases.
Time frame: Up to 5 years
Efficacy Endpoints
The incidence of the first occurrence of of the Nonfatal type 1 myocardial infarction. Measured in number of cases.
Time frame: Up to 5 years
Efficacy Endpoints
The incidence of the first occurrence of the Nonfatal ischemic stroke. Measured in number of cases.
Time frame: Up to 5 years
Efficacy Endpoints
The incidence of the first occurrence of the Urgent coronary revascularization. Measured in number of cases.
Time frame: Up to 5 years
Efficacy Endpoints
Domain "effectiveness" of the Patient satisfaction measured at visit 1 (6 months) using the Treatment Satisfaction Questionnaire for Medication (TSQM) version 1.4 a 14-item psychometric instrument. The TSQM (version 1.4) has 14 questions divided into 4 domains: effectiveness (items 1 to 3), side effects (items 4 to 8), convenience (items 9 to 11), and global satisfaction (items 12 to 14). In this domain (effectiveness) the response was measured on a Likert-type scale of 5 or 7 points. The score is computed by summing the individual TSQM items and then transforming the composite score into a value ranging from 0 to 100, with 0 indicating complete dissatisfaction and 100 indicating complete satisfaction (higher scores reflect higher patient satisfaction with medication).
Time frame: 6 months
Efficacy Endpoints
Domain "Side effects score" of the Patient satisfaction measured at visit 1 (6 months) using the Treatment Satisfaction Questionnaire for Medication (TSQM) version 1.4 a 14-item psychometric instrument. The TSQM has 14 questions divided into 4 domains: effectiveness (items 1 to 3), side effects (items 4 to 8), convenience (items 9 to 11), and global satisfaction (items 12 to 14). In this domain the response was on a Likert-type scale of 5 or 7 points, except for question 4 which a yes/no question about the presence of side effects is asked. If the answer to this question is no (no side effects reported by the participant), other questions will not be asked (questions 5 to 8), and the total score is automatically computed as the maximum of 100. The score is computed by summing the individual TSQM items and then transforming the composite score into a value ranging from 0 to 100, with 0 indicating complete dissatisfaction and 100 indicating complete satisfaction.
Time frame: 6 months
Efficacy Endpoints
Domain "Convenience score" of the Patient satisfaction measured at visit 1 (6 months) using the Treatment Satisfaction Questionnaire for Medication (TSQM) version 1.4 a 14-item psychometric instrument. The TSQM (version 1.4) has 14 questions divided into 4 domains: effectiveness (items 1 to 3), side effects (items 4 to 8), convenience (items 9 to 11), and global satisfaction (items 12 to 14). In this domain (Convenience score) the response was measured on a Likert-type scale of 5 or 7 points. The score is computed by summing the individual TSQM items and then transforming the composite score into a value ranging from 0 to 100, with 0 indicating complete dissatisfaction and 100 indicating complete satisfaction (higher scores reflect higher patient satisfaction with medication).
Time frame: 6 months
Efficacy Endpoints
Domain "Global satisfaction score" of the Patient satisfaction measured at visit 1 (6 months) using the Treatment Satisfaction Questionnaire for Medication (TSQM) version 1.4 a 14-item psychometric instrument. The TSQM (version 1.4) has 14 questions divided into 4 domains: effectiveness (items 1 to 3), side effects (items 4 to 8), convenience (items 9 to 11), and global satisfaction (items 12 to 14). In this domain (Global satisfaction score) the response was measured on a Likert-type scale of 5 or 7 points. The score is computed by summing the individual TSQM items and then transforming the composite score into a value ranging from 0 to 100, with 0 indicating complete dissatisfaction and 100 indicating complete satisfaction (higher scores reflect higher patient satisfaction with medication).
Time frame: 6 months
Efficacy Endpoints
Domain "effectiveness" of the Patient satisfaction measured at visit 3 (24 months) using the Treatment Satisfaction Questionnaire for Medication (TSQM) version 1.4 a 14-item psychometric instrument. The TSQM (version 1.4) has 14 questions divided into 4 domains: effectiveness (items 1 to 3), side effects (items 4 to 8), convenience (items 9 to 11), and global satisfaction (items 12 to 14). In this domain (effectiveness) the response was measured on a Likert-type scale of 5 or 7 points. The score is computed by summing the individual TSQM items and then transforming the composite score into a value ranging from 0 to 100, with 0 indicating complete dissatisfaction and 100 indicating complete satisfaction (higher scores reflect higher patient satisfaction with medication).
Time frame: 24 months
Efficacy Endpoints
Domain "Side effects score" of the Patient satisfaction measured at visit 3 (24 months) using the Treatment Satisfaction Questionnaire for Medication (TSQM) version 1.4 a 14-item psychometric instrument. The TSQM has 14 questions divided into 4 domains: effectiveness (items 1 to 3), side effects (items 4 to 8), convenience (items 9 to 11), and global satisfaction (items 12 to 14). In this domain (Side effects score) the response was on a Likert-type scale of 5 or 7 points, except for question 4 which a yes/no question about the presence of side effects is asked. If the answer to this question is no (no side effects reported by the participant), other questions will not be asked (questions 5 to 8), and the total score is automatically computed as the maximum of 100. The score is computed by summing the individual TSQM items and then transforming the composite score into a value ranging from 0 to 100, with 0 indicating complete dissatisfaction and 100 indicating complete satisfaction.
Time frame: 24 months
Efficacy Endpoints
Domain "Convenience score" of the Patient satisfaction measured at visit 3 (24 months) using the Treatment Satisfaction Questionnaire for Medication (TSQM) version 1.4 a 14-item psychometric instrument. The TSQM (version 1.4) has 14 questions divided into 4 domains: effectiveness (items 1 to 3), side effects (items 4 to 8), convenience (items 9 to 11), and global satisfaction (items 12 to 14). In this domain (Convenience score) the response was measured on a Likert-type scale of 5 or 7 points. The score is computed by summing the individual TSQM items and then transforming the composite score into a value ranging from 0 to 100, with 0 indicating complete dissatisfaction and 100 indicating complete satisfaction (higher scores reflect higher patient satisfaction with medication).
Time frame: 24 months
Efficacy Endpoints
Domain "Global satisfaction score" of the Patient satisfaction measured at visit 3 (24 months) using the Treatment Satisfaction Questionnaire for Medication (TSQM) version 1.4 a 14-item psychometric instrument. The TSQM (version 1.4) has 14 questions divided into 4 domains: effectiveness (items 1 to 3), side effects (items 4 to 8), convenience (items 9 to 11), and global satisfaction (items 12 to 14). In this domain (Global satisfaction score) the response was measured on a Likert-type scale of 5 or 7 points. The score is computed by summing the individual TSQM items and then transforming the composite score into a value ranging from 0 to 100, with 0 indicating complete dissatisfaction and 100 indicating complete satisfaction (higher scores reflect higher patient satisfaction with medication).
Time frame: 24 months
Safety Endpoints
The incidence of the first occurrence of the Non-cardiovascular death. Measured in number of cases.
Time frame: Up to 5 Years
Patients will be recruited across seven countries in Europe (Spain, Italy, Germany, France, Hungary, Poland, and Czech Republic). Patients were ≥65 years old and diagnosed with a type 1 myocardial infarction within 6 months prior to study enrolment.
| Milestone | Treatment Prevention for Secondary CV | Cardiovascular Polypill |
|---|---|---|
| Started | 1241 | 1258 |
| Completed | 1222 | 1228 |
| Not completed | 19 | 30 |
| Withdrew: Lost to follow-up | 12 | 21 |
| Withdrew: Protocol violation | 7 | 9 |
The incidence of the first occurrence of any component of the following composite endpoint, as adjudicated by the Clinical Events Committee: * Cardiovascular death. * Any nonfatal type 1 myocardial infarction. * Any nonfatal ischemic stroke. * Any urgent coronary revascularization not resulting in death.
| number of adjudicated events | Treatment Prevention for Secondary CV | Cardiovascular Polypill |
|---|---|---|
| Major Cardiovascular Adverse Events (MACE) | 156 | 118 |
Treatment adherence at 6 months measured using the Morisky-Medication Adherence Scale (8 item) Questionnaire (MMAS-8). Results: Low adherence (0-5); Medium adherence (6-7) and High adherence (8). The number and percentage of patients with low (0-5), medium (6-7) and high (8) adherence will be reported by treatment group.
| percentage of participants | Treatment Prevention for Secondary CV | Cardiovascular Polypill |
|---|---|---|
| Low adherence (0-5) | 9.5 | 5.5 |
| Medium adherence (6-7) | 27.8 | 24.0 |
| High adherence (8) | 62.7 | 70.6 |
All-cause mortality.
| number of events | Treatment Prevention for Secondary CV | Cardiovascular Polypill |
|---|---|---|
| Safety Endpoints | 117 | 115 |
Treatment adherence at 24 months measured using the Morisky-Medication Adherence Scale (8 item) Questionnaire (MMAS-8). Results: Low adherence (0-5); Medium adherence (6-7) and High adherence (8). The number and percentage of patients with low (0-5), medium (6-7) and high (8) adherence will be reported by treatment group.
| percentage of participants | Treatment Prevention for Secondary CV | Cardiovascular Polypill |
|---|---|---|
| Low adherence (0-5) | 6.9 | 4.2 |
| Medium adherence (6-7) | 29.8 | 21.7 |
| High adherence (8) | 63.2 | 74.1 |
The systolic Blood Pressure measured in millimeters of mercury (mmHg) at visit 1 (6 months). Mean and standard deviation will be reported by treatment group.
| millimeters of mercury (mmHg) | Treatment Prevention for Secondary CV | Cardiovascular Polypill |
|---|---|---|
| Efficacy Endpoints | 134.8 ± 18.1 | 134.4 ± 17.7 |
The systolic Blood Pressure measured in millimeters of mercury (mmHg) at visit 2 (12 months). Mean and standard deviation will be reported by treatment group.
| millimeters of mercury (mmHg) | Treatment Prevention for Secondary CV | Cardiovascular Polypill |
|---|---|---|
| Efficacy Endpoints | 135.0 ± 18.0 | 136.3 ± 17.5 |
The systolic Blood Pressure measured in millimeters of mercury (mmHg) at visit 3 (24 months). Mean and standard deviation will be reported by treatment group.
| millimeters of mercury (mmHg) | Treatment Prevention for Secondary CV | Cardiovascular Polypill |
|---|---|---|
| Efficacy Endpoints | 135.5 ± 17.1 | 135.2 ± 16.9 |
The Diastolic Blood Pressure measured in millimeters of mercury (mmHg) at visit 1 (6 months). Mean and standard deviation will be reported by treatment group. The frequency, mean and standard deviation at each visit will be reported by treatment group.
| millimeters of mercury (mmHg) | Treatment Prevention for Secondary CV | Cardiovascular Polypill |
|---|---|---|
| Efficacy Endpoints | 74.2 ± 9.9 | 74.3 ± 10.2 |
The Diastolic Blood Pressure measured in millimeters of mercury (mmHg) at visit 2 (12 months). Mean and standard deviation will be reported by treatment group. The frequency, mean and standard deviation at each visit will be reported by treatment group.
| millimeters of mercury (mmHg) | Treatment Prevention for Secondary CV | Cardiovascular Polypill |
|---|---|---|
| Efficacy Endpoints | 74.1 ± 9.8 | 74.7 ± 9.9 |
The Diastolic Blood Pressure measured in millimeters of mercury (mmHg) at visit 3 (24 months). Mean and standard deviation will be reported by treatment group. The frequency, mean and standard deviation at each visit will be reported by treatment group.
| millimeters of mercury (mmHg) | Treatment Prevention for Secondary CV | Cardiovascular Polypill |
|---|---|---|
| Efficacy Endpoints | 74.9 ± 9.7 | 74.8 ± 10.1 |
Low-density lipoprotein (LDL) cholesterol levels measured in mg/dL at visit 2 (12 months). Mean and standard deviation will be reported by treatment group. The frequency, mean and standard deviation at each visit will be reported by treatment group.
| mg/dL | Treatment Prevention for Secondary CV | Cardiovascular Polypill |
|---|---|---|
| Efficacy Endpoints | 66.3 ± 25.4 | 69.2 ± 24.7 |
Low-density lipoprotein (LDL) cholesterol levels measured in mg/dL at visit 3 (24 months). Mean and standard deviation will be reported by treatment group. The frequency, mean and standard deviation at each visit will be reported by treatment group.
| mg/dL | Treatment Prevention for Secondary CV | Cardiovascular Polypill |
|---|---|---|
| Efficacy Endpoints | 67.2 ± 25.4 | 67.7 ± 23.6 |
The incidence of the first occurrence of any component of the following composite endpoint, as adjudicated by the Clinical Events Committee: Cardiovascular death (CV death); Acute Myocardial Infarction (MI) type 1; stroke. Measured in number of cases.
| number of events | Treatment Prevention for Secondary CV | Cardiovascular Polypill |
|---|---|---|
| Efficacy Endpoints | 144 | 101 |
The incidence of the first occurrence of the Cardiovascular (CV) death. Measured in number of cases.
| number of events | Treatment Prevention for Secondary CV | Cardiovascular Polypill |
|---|---|---|
| Efficacy Endpoints | 71 | 48 |
The incidence of the first occurrence of of the Nonfatal type 1 myocardial infarction. Measured in number of cases.
| number of events | Treatment Prevention for Secondary CV | Cardiovascular Polypill |
|---|---|---|
| Efficacy Endpoints | 62 | 44 |
The incidence of the first occurrence of the Nonfatal ischemic stroke. Measured in number of cases.
| number of events | Treatment Prevention for Secondary CV | Cardiovascular Polypill |
|---|---|---|
| Efficacy Endpoints | 27 | 19 |
The incidence of the first occurrence of the Urgent coronary revascularization. Measured in number of cases.
| number of events | Treatment Prevention for Secondary CV | Cardiovascular Polypill |
|---|---|---|
| Efficacy Endpoints | 28 | 27 |
Domain "effectiveness" of the Patient satisfaction measured at visit 1 (6 months) using the Treatment Satisfaction Questionnaire for Medication (TSQM) version 1.4 a 14-item psychometric instrument. The TSQM (version 1.4) has 14 questions divided into 4 domains: effectiveness (items 1 to 3), side effects (items 4 to 8), convenience (items 9 to 11), and global satisfaction (items 12 to 14). In this domain (effectiveness) the response was measured on a Likert-type scale of 5 or 7 points. The score is computed by summing the individual TSQM items and then transforming the composite score into a value ranging from 0 to 100, with 0 indicating complete dissatisfaction and 100 indicating complete satisfaction (higher scores reflect higher patient satisfaction with medication).
| score on a scale | Treatment Prevention for Secondary CV | Cardiovascular Polypill |
|---|---|---|
| Efficacy Endpoints | 69.17 ± 17.57 | 72.26 ± 17.85 |
Domain "Side effects score" of the Patient satisfaction measured at visit 1 (6 months) using the Treatment Satisfaction Questionnaire for Medication (TSQM) version 1.4 a 14-item psychometric instrument. The TSQM has 14 questions divided into 4 domains: effectiveness (items 1 to 3), side effects (items 4 to 8), convenience (items 9 to 11), and global satisfaction (items 12 to 14). In this domain the response was on a Likert-type scale of 5 or 7 points, except for question 4 which a yes/no question about the presence of side effects is asked. If the answer to this question is no (no side effects reported by the participant), other questions will not be asked (questions 5 to 8), and the total score is automatically computed as the maximum of 100. The score is computed by summing the individual TSQM items and then transforming the composite score into a value ranging from 0 to 100, with 0 indicating complete dissatisfaction and 100 indicating complete satisfaction.
| score on a scale | Treatment Prevention for Secondary CV | Cardiovascular Polypill |
|---|---|---|
| Efficacy Endpoints | 66.71 ± 23.38 | 61.52 ± 23.18 |
Domain "Convenience score" of the Patient satisfaction measured at visit 1 (6 months) using the Treatment Satisfaction Questionnaire for Medication (TSQM) version 1.4 a 14-item psychometric instrument. The TSQM (version 1.4) has 14 questions divided into 4 domains: effectiveness (items 1 to 3), side effects (items 4 to 8), convenience (items 9 to 11), and global satisfaction (items 12 to 14). In this domain (Convenience score) the response was measured on a Likert-type scale of 5 or 7 points. The score is computed by summing the individual TSQM items and then transforming the composite score into a value ranging from 0 to 100, with 0 indicating complete dissatisfaction and 100 indicating complete satisfaction (higher scores reflect higher patient satisfaction with medication).
| score on a scale | Treatment Prevention for Secondary CV | Cardiovascular Polypill |
|---|---|---|
| Efficacy Endpoints | 69.47 ± 16.87 | 76.56 ± 14.78 |
Domain "Global satisfaction score" of the Patient satisfaction measured at visit 1 (6 months) using the Treatment Satisfaction Questionnaire for Medication (TSQM) version 1.4 a 14-item psychometric instrument. The TSQM (version 1.4) has 14 questions divided into 4 domains: effectiveness (items 1 to 3), side effects (items 4 to 8), convenience (items 9 to 11), and global satisfaction (items 12 to 14). In this domain (Global satisfaction score) the response was measured on a Likert-type scale of 5 or 7 points. The score is computed by summing the individual TSQM items and then transforming the composite score into a value ranging from 0 to 100, with 0 indicating complete dissatisfaction and 100 indicating complete satisfaction (higher scores reflect higher patient satisfaction with medication).
| score on a scale | Treatment Prevention for Secondary CV | Cardiovascular Polypill |
|---|---|---|
| Efficacy Endpoints | 67.71 ± 18.53 | 71.50 ± 18.06 |
Domain "effectiveness" of the Patient satisfaction measured at visit 3 (24 months) using the Treatment Satisfaction Questionnaire for Medication (TSQM) version 1.4 a 14-item psychometric instrument. The TSQM (version 1.4) has 14 questions divided into 4 domains: effectiveness (items 1 to 3), side effects (items 4 to 8), convenience (items 9 to 11), and global satisfaction (items 12 to 14). In this domain (effectiveness) the response was measured on a Likert-type scale of 5 or 7 points. The score is computed by summing the individual TSQM items and then transforming the composite score into a value ranging from 0 to 100, with 0 indicating complete dissatisfaction and 100 indicating complete satisfaction (higher scores reflect higher patient satisfaction with medication).
| score on a scale | Treatment Prevention for Secondary CV | Cardiovascular Polypill |
|---|---|---|
| Efficacy Endpoints | 68.79 ± 17.65 | 74.06 ± 17.86 |
Domain "Side effects score" of the Patient satisfaction measured at visit 3 (24 months) using the Treatment Satisfaction Questionnaire for Medication (TSQM) version 1.4 a 14-item psychometric instrument. The TSQM has 14 questions divided into 4 domains: effectiveness (items 1 to 3), side effects (items 4 to 8), convenience (items 9 to 11), and global satisfaction (items 12 to 14). In this domain (Side effects score) the response was on a Likert-type scale of 5 or 7 points, except for question 4 which a yes/no question about the presence of side effects is asked. If the answer to this question is no (no side effects reported by the participant), other questions will not be asked (questions 5 to 8), and the total score is automatically computed as the maximum of 100. The score is computed by summing the individual TSQM items and then transforming the composite score into a value ranging from 0 to 100, with 0 indicating complete dissatisfaction and 100 indicating complete satisfaction.
| score on a scale | Treatment Prevention for Secondary CV | Cardiovascular Polypill |
|---|---|---|
| Efficacy Endpoints | 64.20 ± 23.14 | 68.75 ± 24.83 |
Domain "Convenience score" of the Patient satisfaction measured at visit 3 (24 months) using the Treatment Satisfaction Questionnaire for Medication (TSQM) version 1.4 a 14-item psychometric instrument. The TSQM (version 1.4) has 14 questions divided into 4 domains: effectiveness (items 1 to 3), side effects (items 4 to 8), convenience (items 9 to 11), and global satisfaction (items 12 to 14). In this domain (Convenience score) the response was measured on a Likert-type scale of 5 or 7 points. The score is computed by summing the individual TSQM items and then transforming the composite score into a value ranging from 0 to 100, with 0 indicating complete dissatisfaction and 100 indicating complete satisfaction (higher scores reflect higher patient satisfaction with medication).
| score on a scale | Treatment Prevention for Secondary CV | Cardiovascular Polypill |
|---|---|---|
| Efficacy Endpoints | 70.19 ± 17.06 | 77.30 ± 15.95 |
Domain "Global satisfaction score" of the Patient satisfaction measured at visit 3 (24 months) using the Treatment Satisfaction Questionnaire for Medication (TSQM) version 1.4 a 14-item psychometric instrument. The TSQM (version 1.4) has 14 questions divided into 4 domains: effectiveness (items 1 to 3), side effects (items 4 to 8), convenience (items 9 to 11), and global satisfaction (items 12 to 14). In this domain (Global satisfaction score) the response was measured on a Likert-type scale of 5 or 7 points. The score is computed by summing the individual TSQM items and then transforming the composite score into a value ranging from 0 to 100, with 0 indicating complete dissatisfaction and 100 indicating complete satisfaction (higher scores reflect higher patient satisfaction with medication).
| score on a scale | Treatment Prevention for Secondary CV | Cardiovascular Polypill |
|---|---|---|
| Efficacy Endpoints | 67.76 ± 17.87 | 74.36 ± 17.52 |
The incidence of the first occurrence of the Non-cardiovascular death. Measured in number of cases.
| number of events | Treatment Prevention for Secondary CV | Cardiovascular Polypill |
|---|---|---|
| Safety Endpoints | 46 | 67 |
Collected over Up to 5 Years.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Treatment Prevention for Secondary CV | 117/1,229 (9.5%) | 220/1,229 (17.9%) | 388/1,229 (31.6%) |
| Cardiovascular Polypill | 115/1,237 (9.3%) | 248/1,237 (20%) | 404/1,237 (32.7%) |
| Event | Treatment Prevention for Secondary CV | Cardiovascular Polypill |
|---|---|---|
| pneumoniaInfections and infestations | 17/1229 | 14/1237 |
| chest painGeneral disorders | 15/1229 | 10/1237 |
| covid-19 pneumoniaInfections and infestations | 10/1229 | 11/1237 |
| anaemiaBlood and lymphatic system disorders | 9/1229 | 10/1237 |
| acute kidney injuryRenal and urinary disorders | 9/1229 | 9/1237 |
| urinary tract infectionInfections and infestations | 9/1229 | 6/1237 |
| covid-19Infections and infestations | 5/1229 | 9/1237 |
| cardiac failureCardiac disorders | 1/1229 | 8/1237 |
| gastrointestinal haemorrhageGastrointestinal disorders | 4/1229 | 8/1237 |
| haematuriaRenal and urinary disorders | 7/1229 | 4/1237 |
| Event | Treatment Prevention for Secondary CV | Cardiovascular Polypill |
|---|---|---|
| CoughRespiratory, thoracic and mediastinal disorders | 43/1229 | 49/1237 |
| Chest painGeneral disorders | 28/1229 | 16/1237 |
| HypotensionVascular disorders | 15/1229 | 26/1237 |
| MyalgiaMusculoskeletal and connective tissue disorders | 25/1229 | 14/1237 |
| HypertensionVascular disorders | 20/1229 | 22/1237 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 20/1229 | 17/1237 |
| Atrial fibrillationCardiac disorders | 19/1229 | 16/1237 |
| SyncopeNervous system disorders | 15/1229 | 8/1237 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 14/1229 | 13/1237 |
| AnaemiaBlood and lymphatic system disorders | 13/1229 | 12/1237 |
A total of 2499 participants (Treatment Prevention for Secondary CV - 1241; Cardiovascular Polypill - 1258) were included in the study. A total of 33 (Treatment Prevention for Secondary CV - 12; Cardiovascular Polypill - 21) participants were lost to follow-up as described in the "Results Participant Flow". The results were presented for a total of 1229 participants in the "Treatment Prevention for Secondary CV" and 1237 participants in the "Cardiovascular Polypill".
| Age, Categorical(Participants) | Treatment Prevention for Secondary CV | Cardiovascular Polypill | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 0 | 0 | 0 |
| >=65 years | 1229 | 1237 | 2466 |
| Sex: Female, Male(Participants) | Treatment Prevention for Secondary CV | Cardiovascular Polypill | Total |
|---|---|---|---|
| Female | 381 | 384 | 765 |
| Male | 848 | 853 | 1701 |
| Race (NIH/OMB)(Participants) | Treatment Prevention for Secondary CV | Cardiovascular Polypill | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 3 | 3 |
| White | 1211 | 1221 | 2432 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 18 | 13 | 31 |
| Region of Enrollment(participants) | Treatment Prevention for Secondary CV | Cardiovascular Polypill | Total |
|---|---|---|---|
| Hungary | 45 | 45 | 90 |
| Czechia | 87 | 85 | 172 |
| Poland | 60 | 63 | 123 |
| Italy | 365 | 366 | 731 |
| France | 70 | 74 | 144 |
| Germany | 184 | 182 | 366 |
| Spain | 418 | 422 | 840 |
Showing the first 100 of 113 sites across 7 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
The record gives a start of Jul 2016, a primary completion of Oct 2021 and a completion of Mar 2022. It does not say whether these dates are actual or estimated.
Results were first posted in May 2025, 3 years 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III